By: Michael Rigas, Pharm.D., FNHIA Biosimilars are also known as follow-on biologics or subsequent-entry biologics. They are FDA-approved copies of the original “innovator” drug product that […]
By: Ty Bello, BS, RCC The objective of this article is to provide information with application so you, as an Independent Ambulatory Infusion Center, can either […]
By: Kay Coulter, RN, CRNI, VA-BC In the insurance industry there’s a saying about how you don’t know you’re facing litigation until it’s too late. Ambulatory […]
What’s behind the recent surge of investments into the infusion industry? The ambulatory infusion center (AIC) industry has seen a significant surge in investment in recent […]